Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Neurology ; 72(5): 396-401, 2009 Feb 03.
Article in English | MEDLINE | ID: mdl-18987352

ABSTRACT

OBJECTIVE: Natalizumab is a humanized recombinant monoclonal antibody against very late activation antigen-4 approved for the treatment of patients with multiple sclerosis (MS). A phase II study failed to demonstrate a difference between natalizumab treatment groups and the placebo group with regard to gadolinium enhancing lesions on MRI 3 months after discontinuation of therapy. The objective of this study was to assess clinical MS disease activity, surrogate disease markers on MRI, immunologic parameters in peripheral blood and CSF, as well as safety in patients with MS after discontinuation of natalizumab therapy. METHODS: This study is a longitudinal and serial cross-sectional assessment, in which 23 patients who were treated with natalizumab in the context of two phase III clinical trials were originally enrolled. A subgroup of patients was followed over 14 months. The annual relapse rate, neurologic disease progression assessed by the Expanded Disability Status Scale, disease surrogate markers on MRI, cellular and humoral immune markers in peripheral blood and CSF, and adverse events of the drug were monitored. RESULTS: With regard to clinical disease activity, neuroimaging, and immune responses, the majority of patients in our cohort were stable. Decreased lymphocyte cell numbers and altered cell ratios returned to normal 14 months after cessation of natalizumab. No infectious complications were observed. CONCLUSION: This is the first long-term follow-up of patients who discontinued natalizumab. We did not observe a clinical, radiographic, or immunologic rebound phenomenon after discontinuation of natalizumab therapy.


Subject(s)
Antibodies, Monoclonal/adverse effects , Central Nervous System/drug effects , Multiple Sclerosis/drug therapy , Adult , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal, Humanized , Biomarkers/blood , Biomarkers/cerebrospinal fluid , Central Nervous System/immunology , Central Nervous System/pathology , Cross-Sectional Studies , Disability Evaluation , Disease Progression , Female , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/adverse effects , Longitudinal Studies , Magnetic Resonance Imaging , Male , Middle Aged , Multiple Sclerosis/immunology , Multiple Sclerosis/pathology , Natalizumab , Outcome Assessment, Health Care/methods , Recurrence , Severity of Illness Index , Treatment Outcome
2.
Scand J Immunol ; 65(6): 514-24, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17523943

ABSTRACT

Human antigen presenting cells (APC) found in peripheral blood are considered to be precursors that have been released from the bone marrow and are in transit to the peripheral tissues. These APC populations include myeloid dendritic cells (mDC), plasmacytoid DC (pDC) and monocytes (Mo). To assign specialized functional roles and stages of development for APCs, CD33 expressing APC subsets were examined for their capacity to respond to chemokines. Three major CD33(+) subsets including CD33(bright)CD14(bright) Mo, CD33(bright)CD14(-) CD11c(+) mDC and CD33(dim)CD14(-) pDC were present. Dendritic cells subsets and Mo expressed low levels of CC and CXC receptors, but distinctive chemokine receptor expression profiles were not observed. The percentage of cells expressing a particular chemokine receptor varied from donor to donor and over time in the same donor. Myeloid DC and Mo but not pDC migrated toward CXCL12 in a concentration dependent manner. Monocytes and pDC, but not myeloid DC, were attracted by high concentrations of CXCL10. All CD33(+) subsets migrated in a concentration dependent manner toward CCL19, but responded less robustly to CCL21. CCL20 was not chemoattractant for any population. Despite the finding that APC did not exhibit unique surface chemokine receptor expression patterns, they exhibited differential migration to CXCL12, CXCL10 and CCL21 but not to CCL20 or CCL19.


Subject(s)
Antigen-Presenting Cells/immunology , Cell Movement/immunology , Dendritic Cells/immunology , Monocytes/immunology , Plasma Cells/immunology , Receptors, Chemokine/metabolism , Antigen-Presenting Cells/classification , Antigens, CD/analysis , Antigens, CD/blood , Antigens, Differentiation, Myelomonocytic , Biomarkers , Cell Lineage , Cell Separation , Flow Cytometry , Humans , Immunophenotyping , Lipopolysaccharide Receptors , Sialic Acid Binding Ig-like Lectin 3
SELECTION OF CITATIONS
SEARCH DETAIL
...